To include your compound in the COVID-19 Resource Center, submit it here.

Verastem down on duvelisib update at ASH

Verastem Inc. (NASDAQ:VSTM) fell $0.73 (17%) to $3.60 on Monday after reporting additional data from the Phase III DUO trial evaluating duvelisib (IPI-145) to treat relapsed or

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE